Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma

Oncology Letters

Volumn 11, Issue 2, 2016, Pages 1581-1585

  Khoja, Leila ^a   Atenafu, Eshetu G ^a   Ye, Qian ^a   Gedye, Craig ^a   Chappell, Maryanne ^a   Hogg, David ^a   Butler, Marcus O ^a   Joshua, Anthony M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Checkpoint inhibitors; Immune related adverse events; Ipilimumab; Melanoma; Pembrolizumab; Toxicity

Indexed keywords

INFLIXIMAB; IPILIMUMAB; PREDNISONE; THYROXINE;

ADULT; AGED; ARTHRITIS; ARTICLE; BONE METASTASIS; CLINICAL FEATURE; COLITIS; DIARRHEA; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; HYPOPHYSITIS; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYOSITIS; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; THYROID DISEASE; TREATMENT OUTCOME; VERY ELDERLY;

EID: 84954338893     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.4069     Document Type: Article

References (12)

1. Canadian Cancer Society: Canadian Cancer Statistics. http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=sk. Accessed 1 August 2014.
2. Gedye C, Hogg D, Butler M and Joshua AM: New treatments for metastatic melanoma. CMAJ 186: 754-760, 2014.
3. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010.
4. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011.
5. Schadendorf D, Robert C, Weber JS, et al: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. J Clin Oncol 33: 1889-1894, 2015.
6. Tarhini A: Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: The underlying mechanisms and clinical management. Scientifica (Cairo) 2013: 857519, 2013.
7. Topalian SL, Sznol M, McDermott DF, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32: 1020-1030, 2014.
8. Robert C, Ribas A, Wolchok JD, et al: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 384: 1109-1117, 2014.
9. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al: Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. ASCO Meeting Abstracts 32: LBA9008, 2014.
10. Johnson DB, Lovly CM, Flavin M, et al: NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM). ASCO Meeting Abstracts 31: 9019, 2013.
11. Zimmerman ZF, Storer B, Godara A, et al: Outcomes and clinical markers associated with benefit from ipilimumab (Ipi) in patients with advanced melanoma: A retrospective single-institution study. ASCO Meeting Abstracts 31: e20048, 2013.
12. Kelderman S, Heemskerk B, van Tinteren H, et al: Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 63: 449-458, 2014.